➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Harvard Business School
McKesson
McKinsey
Dow

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

Patent: 9,572,788

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 9,572,788
Title:Cell permeable inhibitors of anaphase promoting complex
Abstract: The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.
Inventor(s): King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Application Number:14/276,994
Patent Claims:see list of patent claims

Details for Patent 9,572,788

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 2019-02-28 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 2017-06-22 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX Orphan search
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin VIAL;SINGLE-DOSE 761060 2018-04-09 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX Orphan search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125399 2011-08-19 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX search
Seattle Genetics ADCETRIS brentuximab vedotin INJECTABLE; INJECTION 125388 2011-08-19 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 2011-03-25 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX Orphan search
Novartis KESIMPTA ofatumumab SOLUTION;SUBCUTANEOUS 125326 2009-10-26 ⤷  Free Forever Trial President and Fellows of Harvard College (Cambridge, MA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
McKesson
Mallinckrodt
Boehringer Ingelheim
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.